Moderna Joins Top S&P 500 Firms as Stock Value Triples_老虎社区_美港股上老虎

Moderna Joins Top S&P 500 Firms as Stock Value Triples

Bloomberg2021-07-22

(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile. The move caps the drugmaker’s transformation from an early-stage biotech to...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

Guardian91
·2021-07-22
Vaccination is more of a necessity for the next 5 years till the world has more or less achieved herd immunity. Moderna can hold the spot for awhilebut it need to innovate or have other high efficiency drugs for any further long term growth potential. 🤔
回复
点赞
举报
Shank88
·2021-07-22
The constant need for vaccines and boostershots will Ensure consistent profitability. Cheap? Maybe not.
回复
点赞
举报
377tkr
·2021-07-22
How true?
回复
点赞
举报
xiaochan
·2021-07-22
Wow! Go go go!!
回复
点赞
举报
TriciaChang
·2021-07-22
Ok
回复
2
举报
收起
- Stefffunnyyy:
  Good
  2021-07-22
  回复
  举报
QqSM
·2021-07-22
Great summary. Thanks
回复
3
举报
收起
- Sm9999:
  Kk
  2021-07-22
  回复
  举报
LancetAeon
·2021-07-22
I got morderna shot and got really sore back
回复
4
举报
收起
- Sebas997:
  true
  2021-07-22
  回复
  举报
- Akong:
  Nice
  2021-07-22
  回复
  举报
Rudyy
·2021-07-22
Like!
回复
2
举报
收起
- 王虎V:
  liked
  2021-07-22
  回复
  举报
Cate
·2021-07-22
Like
回复
2
举报
oneiminion
·2021-07-22
Please like [Shy]
回复
6
举报
收起
- Maybl:
  👍
  2021-07-22
  回复
  举报
- Dac19:
  Done
  2021-07-22
  回复
  举报
Dan1192
·2021-07-22
Please like and comment my reply. Thanks in advance
回复
4
举报
收起
- oneiminion:
  Done
  2021-07-22
  回复
  举报
Howhowlee
·2021-07-22
like 🙏
回复
4
举报
收起
- neoyoucai:
  Like 🙏🏼
  2021-07-22
  回复
  举报
Allenchang
·2021-07-22
Like and comment please
回复
3
举报
Ahsiang
·2021-07-22
Oh yeah
回复
3
举报
HillaryV
·2021-07-22
Woah
回复
4
举报

热议股票

7x24

全部

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/1105130573?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-07-22 10:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105130573","market":"us","top_or_hot":-1,"title":"Moderna Joins Top S&P 500 Firms as Stock Value Triples","media":"Bloomberg","content":"<div>\n(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.\nThe move caps the drugmaker’s transformation from an early-stage biotech to...\n\n<a href=\"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html\">网页链接</a>\n\n</div>\n","source":"lsy1612507957220","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Joins Top S&P 500 Firms as Stock Value Triples</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Joins Top S&P 500 Firms as Stock Value Triples\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 10:43 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html>Bloomberg</a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.\nThe move caps the drugmaker’s transformation from an early-stage biotech to...\n\n<a href=\"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MRNA","symbol_name":"Moderna, Inc.","start_time":0,"source_url":"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html","article_id":"1105130573","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105130573","pubTimestamp":1626921817,"columns":[],"sourceInfo":{"source_id":"lsy1612507957220","name":"finance.yahoo"},"weMediaInfo":null,"summary":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"MRNA":"Moderna, Inc."},"translate_title":"莫德纳加入标普500顶级公司，股价上涨两倍","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRNA":0.9},"content_text":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.\nThe move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.\nIn the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.\nModerna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.\nThe company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.\nBut the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.\nShares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.\nSkeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.\nStill, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.\nA survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.\n“In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”\nSales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[{"id":172358852,"gmtCreate":1626939561876,"gmtModify":1633769554457,"author":{"id":"3572064005702971","authorId":"3572064005702971","name":"Guardian91","avatar":"https://static.tigerbbs.com/e4a68d7a51e72bf7de3fb84741373219","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3572064005702971","idStr":"3572064005702971"},"htmlText":"Vaccination is more of a&nbsp;necessity for the next 5 years till the world has more or less achieved herd immunity. Moderna can hold the spot for awhilebut it need to innovate or have other high efficiency drugs for any further long term growth potential. 🤔","listText":"Vaccination is more of a&nbsp;necessity for the next 5 years till the world has more or less achieved herd immunity. Moderna can hold the spot for awhilebut it need to innovate or have other high efficiency drugs for any further long term growth potential. 🤔","text":"Vaccination is more of a necessity for the next 5 years till the world has more or less achieved herd immunity. Moderna can hold the spot for awhilebut it need to innovate or have other high efficiency drugs for any further long term growth potential. 🤔","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172358852","repostId":1105130573,"repostType":4,"repost":{"id":"1105130573","kind":"news","pubTimestamp":1626921817,"share":"https://www.laohu8.com/m/news/1105130573?lang=zh_CN&edition=full","pubTime":"2021-07-22 10:43","market":"us","language":"en","title":"Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105130573","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock","content":"(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBloomberg2021-07-22 10:43\n\n</h4>\n</header>\n<article>\n(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html\">Bloomberg</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105130573","content_text":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.\nThe move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.\nIn the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.\nModerna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.\nThe company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.\nBut the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.\nShares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.\nSkeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.\nStill, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.\nA survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.\n“In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”\nSales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":172979708,"gmtCreate":1626931113004,"gmtModify":1633769606944,"author":{"id":"3555541900193425","authorId":"3555541900193425","name":"Shank88","avatar":"https://static.tigerbbs.com/a154c05a17a8a27be584e08972979b04","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3555541900193425","idStr":"3555541900193425"},"htmlText":"The constant need for vaccines and boostershots will Ensure consistent profitability. Cheap? Maybe not.","listText":"The constant need for vaccines and boostershots will Ensure consistent profitability. Cheap? Maybe not.","text":"The constant need for vaccines and boostershots will Ensure consistent profitability. Cheap? Maybe not.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172979708","repostId":1105130573,"repostType":4,"repost":{"id":"1105130573","kind":"news","pubTimestamp":1626921817,"share":"https://www.laohu8.com/m/news/1105130573?lang=zh_CN&edition=full","pubTime":"2021-07-22 10:43","market":"us","language":"en","title":"Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105130573","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock","content":"(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBloomberg2021-07-22 10:43\n\n</h4>\n</header>\n<article>\n(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html\">Bloomberg</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105130573","content_text":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.\nThe move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.\nIn the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.\nModerna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.\nThe company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.\nBut the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.\nShares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.\nSkeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.\nStill, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.\nA survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.\n“In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”\nSales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":172939489,"gmtCreate":1626925807341,"gmtModify":1633769660076,"author":{"id":"3582001642809284","authorId":"3582001642809284","name":"377tkr","avatar":"https://static.tigerbbs.com/25cbfadab64a300119ffe30a37937ff2","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3582001642809284","idStr":"3582001642809284"},"htmlText":"How true?","listText":"How true?","text":"How true?","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172939489","repostId":1105130573,"repostType":4,"repost":{"id":"1105130573","kind":"news","pubTimestamp":1626921817,"share":"https://www.laohu8.com/m/news/1105130573?lang=zh_CN&edition=full","pubTime":"2021-07-22 10:43","market":"us","language":"en","title":"Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105130573","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock","content":"(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBloomberg2021-07-22 10:43\n\n</h4>\n</header>\n<article>\n(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html\">Bloomberg</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105130573","content_text":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.\nThe move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.\nIn the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.\nModerna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.\nThe company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.\nBut the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.\nShares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.\nSkeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.\nStill, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.\nA survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.\n“In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”\nSales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":172997880,"gmtCreate":1626925631040,"gmtModify":1633769661730,"author":{"id":"3570343633899015","authorId":"3570343633899015","name":"xiaochan","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3570343633899015","idStr":"3570343633899015"},"htmlText":"Wow! Go go go!!&nbsp;","listText":"Wow! Go go go!!&nbsp;","text":"Wow! Go go go!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172997880","repostId":1105130573,"repostType":4,"repost":{"id":"1105130573","kind":"news","pubTimestamp":1626921817,"share":"https://www.laohu8.com/m/news/1105130573?lang=zh_CN&edition=full","pubTime":"2021-07-22 10:43","market":"us","language":"en","title":"Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105130573","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock","content":"(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBloomberg2021-07-22 10:43\n\n</h4>\n</header>\n<article>\n(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html\">Bloomberg</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105130573","content_text":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.\nThe move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.\nIn the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.\nModerna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.\nThe company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.\nBut the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.\nShares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.\nSkeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.\nStill, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.\nA survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.\n“In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”\nSales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":172078081,"gmtCreate":1626923969943,"gmtModify":1633769680095,"author":{"id":"3560421500323385","authorId":"3560421500323385","name":"TriciaChang","avatar":"https://static.tigerbbs.com/5cb6619edb253a8bb8b2776c7d9b0e02","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3560421500323385","idStr":"3560421500323385"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/172078081","repostId":1105130573,"repostType":4,"repost":{"id":"1105130573","kind":"news","pubTimestamp":1626921817,"share":"https://www.laohu8.com/m/news/1105130573?lang=zh_CN&edition=full","pubTime":"2021-07-22 10:43","market":"us","language":"en","title":"Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105130573","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock","content":"(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBloomberg2021-07-22 10:43\n\n</h4>\n</header>\n<article>\n(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html\">Bloomberg</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105130573","content_text":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.\nThe move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.\nIn the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.\nModerna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.\nThe company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.\nBut the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.\nShares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.\nSkeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.\nStill, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.\nA survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.\n“In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”\nSales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5290204,"gmtCreate":1626924187508,"gmtModify":1635224008817,"authorId":3569571463653731,"author":{"id":3569571463653731,"idStr":"3569571463653731","authorId":3569571463653731,"name":"Stefffunnyyy","avatar":"https://static.tigerbbs.com/0f4caf72fd5910b8e8eecf36a72faded","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":172078081,"type":1,"supId":0,"prevId":0,"content":"Good","text":"Good","html":"Good"}],"langContent":"EN"},{"id":172079396,"gmtCreate":1626923784415,"gmtModify":1633769681907,"author":{"id":"3585797482260363","authorId":"3585797482260363","name":"QqSM","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3585797482260363","idStr":"3585797482260363"},"htmlText":"Great summary. Thanks","listText":"Great summary. Thanks","text":"Great summary. Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/172079396","repostId":1105130573,"repostType":4,"repost":{"id":"1105130573","kind":"news","pubTimestamp":1626921817,"share":"https://www.laohu8.com/m/news/1105130573?lang=zh_CN&edition=full","pubTime":"2021-07-22 10:43","market":"us","language":"en","title":"Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105130573","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock","content":"(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBloomberg2021-07-22 10:43\n\n</h4>\n</header>\n<article>\n(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html\">Bloomberg</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105130573","content_text":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.\nThe move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.\nIn the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.\nModerna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.\nThe company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.\nBut the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.\nShares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.\nSkeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.\nStill, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.\nA survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.\n“In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”\nSales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5290313,"gmtCreate":1626925114216,"gmtModify":1635224000504,"authorId":3556603880908436,"author":{"id":3556603880908436,"idStr":"3556603880908436","authorId":3556603880908436,"name":"Sm9999","avatar":"https://static.tigerbbs.com/f22a01c260a2d3210c64d83a162185c8","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":172079396,"type":1,"supId":0,"prevId":0,"content":"Kk","text":"Kk","html":"Kk"}],"langContent":"EN"},{"id":172057900,"gmtCreate":1626923018200,"gmtModify":1633769689025,"author":{"id":"3585284420886130","authorId":"3585284420886130","name":"LancetAeon","avatar":"https://static.tigerbbs.com/dee20d63780d522a952021ff6acccef1","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3585284420886130","idStr":"3585284420886130"},"htmlText":"I got morderna shot and got really sore back","listText":"I got morderna shot and got really sore back","text":"I got morderna shot and got really sore back","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/172057900","repostId":1105130573,"repostType":4,"repost":{"id":"1105130573","kind":"news","pubTimestamp":1626921817,"share":"https://www.laohu8.com/m/news/1105130573?lang=zh_CN&edition=full","pubTime":"2021-07-22 10:43","market":"us","language":"en","title":"Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105130573","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock","content":"(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBloomberg2021-07-22 10:43\n\n</h4>\n</header>\n<article>\n(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html\">Bloomberg</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105130573","content_text":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.\nThe move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.\nIn the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.\nModerna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.\nThe company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.\nBut the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.\nShares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.\nSkeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.\nStill, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.\nA survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.\n“In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”\nSales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5290072,"gmtCreate":1626923169544,"gmtModify":1635224018932,"authorId":3574939149444540,"author":{"id":3574939149444540,"idStr":"3574939149444540","authorId":3574939149444540,"name":"Sebas997","avatar":"https://static.tigerbbs.com/3f8d93c1ba9f0a0ae56af713df14b69f","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":172057900,"type":1,"supId":0,"prevId":0,"content":"true","text":"true","html":"true"},{"id":5290081,"gmtCreate":1626923240278,"gmtModify":1635224017955,"authorId":3581597141239825,"author":{"id":3581597141239825,"idStr":"3581597141239825","authorId":3581597141239825,"name":"Akong","avatar":"https://static.tigerbbs.com/96ef9576f2a71f64f1eef29ae49cf365","vip":1,"crmLevel":12,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":172057900,"type":1,"supId":0,"prevId":0,"content":"Nice","text":"Nice","html":"Nice"}],"langContent":"EN"},{"id":172052414,"gmtCreate":1626922849038,"gmtModify":1633769690713,"author":{"id":"3573013786940329","authorId":"3573013786940329","name":"Rudyy","avatar":"https://static.tigerbbs.com/bb9e738a6e83bd49057ffbf45051da2a","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3573013786940329","idStr":"3573013786940329"},"htmlText":"Like!","listText":"Like!","text":"Like!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/172052414","repostId":1105130573,"repostType":4,"repost":{"id":"1105130573","kind":"news","pubTimestamp":1626921817,"share":"https://www.laohu8.com/m/news/1105130573?lang=zh_CN&edition=full","pubTime":"2021-07-22 10:43","market":"us","language":"en","title":"Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105130573","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock","content":"(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBloomberg2021-07-22 10:43\n\n</h4>\n</header>\n<article>\n(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html\">Bloomberg</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105130573","content_text":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.\nThe move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.\nIn the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.\nModerna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.\nThe company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.\nBut the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.\nShares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.\nSkeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.\nStill, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.\nA survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.\n“In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”\nSales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5290039,"gmtCreate":1626922962086,"gmtModify":1635224022084,"authorId":3570938566541704,"author":{"id":3570938566541704,"idStr":"3570938566541704","authorId":3570938566541704,"name":"王虎V","avatar":"https://static.tigerbbs.com/49ea46c7d8ca735c2b0014844e08b2c5","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":172052414,"type":1,"supId":0,"prevId":0,"content":"liked","text":"liked","html":"liked"}],"langContent":"EN"},{"id":172052109,"gmtCreate":1626922832801,"gmtModify":1633769691082,"author":{"id":"4089985658766160","authorId":"4089985658766160","name":"Cate","avatar":"https://static.tigerbbs.com/0977378887b56c38a6458ba69ca5d184","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"4089985658766160","idStr":"4089985658766160"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172052109","repostId":1105130573,"repostType":4,"repost":{"id":"1105130573","kind":"news","pubTimestamp":1626921817,"share":"https://www.laohu8.com/m/news/1105130573?lang=zh_CN&edition=full","pubTime":"2021-07-22 10:43","market":"us","language":"en","title":"Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105130573","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock","content":"(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBloomberg2021-07-22 10:43\n\n</h4>\n</header>\n<article>\n(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html\">Bloomberg</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105130573","content_text":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.\nThe move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.\nIn the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.\nModerna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.\nThe company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.\nBut the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.\nShares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.\nSkeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.\nStill, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.\nA survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.\n“In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”\nSales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":172051684,"gmtCreate":1626922604048,"gmtModify":1631891522764,"author":{"id":"4088392385154590","authorId":"4088392385154590","name":"oneiminion","avatar":"https://static.tigerbbs.com/37399cd4366ce5b166d0a35a9cfb7b53","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"4088392385154590","idStr":"4088392385154590"},"htmlText":"Please like [Shy]&nbsp;","listText":"Please like [Shy]&nbsp;","text":"Please like [Shy]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/172051684","repostId":1105130573,"repostType":4,"repost":{"id":"1105130573","kind":"news","pubTimestamp":1626921817,"share":"https://www.laohu8.com/m/news/1105130573?lang=zh_CN&edition=full","pubTime":"2021-07-22 10:43","market":"us","language":"en","title":"Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105130573","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock","content":"(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBloomberg2021-07-22 10:43\n\n</h4>\n</header>\n<article>\n(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html\">Bloomberg</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105130573","content_text":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.\nThe move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.\nIn the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.\nModerna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.\nThe company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.\nBut the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.\nShares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.\nSkeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.\nStill, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.\nA survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.\n“In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”\nSales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5290115,"gmtCreate":1626923495911,"gmtModify":1631891526071,"authorId":4087686543844860,"author":{"id":4087686543844860,"idStr":"4087686543844860","authorId":4087686543844860,"name":"Maybl","avatar":"https://static.tigerbbs.com/8528a3b3e7bad2aa55b4c86ab0e2cedc","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":172051684,"type":1,"supId":5290076,"prevId":0,"content":"👍","text":"👍","html":"👍"},{"id":5290076,"gmtCreate":1626923183717,"gmtModify":1631891526059,"authorId":3581982556682195,"author":{"id":3581982556682195,"idStr":"3581982556682195","authorId":3581982556682195,"name":"Dac19","avatar":"https://static.tigerbbs.com/82e91a13f45be8e9732185d50df6e7bf","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":172051684,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"EN"},{"id":172053856,"gmtCreate":1626922516775,"gmtModify":1631891126967,"author":{"id":"3580519485452891","authorId":"3580519485452891","name":"Dan1192","avatar":"https://static.tigerbbs.com/42f4372e616e166924268e7ce84613a9","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3580519485452891","idStr":"3580519485452891"},"htmlText":"Please like and comment my reply. Thanks in advance&nbsp;","listText":"Please like and comment my reply. Thanks in advance&nbsp;","text":"Please like and comment my reply. Thanks in advance","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/172053856","repostId":1105130573,"repostType":4,"repost":{"id":"1105130573","kind":"news","pubTimestamp":1626921817,"share":"https://www.laohu8.com/m/news/1105130573?lang=zh_CN&edition=full","pubTime":"2021-07-22 10:43","market":"us","language":"en","title":"Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105130573","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock","content":"(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBloomberg2021-07-22 10:43\n\n</h4>\n</header>\n<article>\n(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html\">Bloomberg</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105130573","content_text":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.\nThe move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.\nIn the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.\nModerna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.\nThe company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.\nBut the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.\nShares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.\nSkeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.\nStill, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.\nA survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.\n“In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”\nSales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5289969,"gmtCreate":1626922586916,"gmtModify":1631891126966,"authorId":4088392385154590,"author":{"id":4088392385154590,"idStr":"4088392385154590","authorId":4088392385154590,"name":"oneiminion","avatar":"https://static.tigerbbs.com/37399cd4366ce5b166d0a35a9cfb7b53","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":172053856,"type":1,"supId":0,"prevId":0,"content":"Done","text":"Done","html":"Done"}],"langContent":"EN"},{"id":172059758,"gmtCreate":1626922465574,"gmtModify":1633769693660,"author":{"id":"3580900560629850","authorId":"3580900560629850","name":"Howhowlee","avatar":"https://static.tigerbbs.com/822aeb8e69b9aec5e6edcbed4485037d","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3580900560629850","idStr":"3580900560629850"},"htmlText":"like 🙏","listText":"like 🙏","text":"like 🙏","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/172059758","repostId":1105130573,"repostType":4,"repost":{"id":"1105130573","kind":"news","pubTimestamp":1626921817,"share":"https://www.laohu8.com/m/news/1105130573?lang=zh_CN&edition=full","pubTime":"2021-07-22 10:43","market":"us","language":"en","title":"Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105130573","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock","content":"(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBloomberg2021-07-22 10:43\n\n</h4>\n</header>\n<article>\n(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html\">Bloomberg</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105130573","content_text":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.\nThe move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.\nIn the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.\nModerna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.\nThe company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.\nBut the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.\nShares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.\nSkeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.\nStill, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.\nA survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.\n“In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”\nSales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":5289957,"gmtCreate":1626922499430,"gmtModify":1635224028268,"authorId":3577323007405835,"author":{"id":3577323007405835,"idStr":"3577323007405835","authorId":3577323007405835,"name":"neoyoucai","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":11,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":172059758,"type":1,"supId":0,"prevId":0,"content":"Like 🙏🏼","text":"Like 🙏🏼","html":"Like 🙏🏼"}],"langContent":"EN"},{"id":172059039,"gmtCreate":1626922400921,"gmtModify":1633769694007,"author":{"id":"3574228994035411","authorId":"3574228994035411","name":"Allenchang","avatar":"https://static.tigerbbs.com/bf64d942e55f3c756282ca09ce5d0be6","vip":1,"crmLevel":12,"crmLevelSwitch":0,"authorIdStr":"3574228994035411","idStr":"3574228994035411"},"htmlText":"Like and comment please&nbsp;","listText":"Like and comment please&nbsp;","text":"Like and comment please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172059039","repostId":1105130573,"repostType":4,"repost":{"id":"1105130573","kind":"news","pubTimestamp":1626921817,"share":"https://www.laohu8.com/m/news/1105130573?lang=zh_CN&edition=full","pubTime":"2021-07-22 10:43","market":"us","language":"en","title":"Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105130573","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock","content":"(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBloomberg2021-07-22 10:43\n\n</h4>\n</header>\n<article>\n(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html\">Bloomberg</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105130573","content_text":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.\nThe move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.\nIn the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.\nModerna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.\nThe company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.\nBut the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.\nShares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.\nSkeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.\nStill, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.\nA survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.\n“In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”\nSales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":172028748,"gmtCreate":1626921953984,"gmtModify":1633769697879,"author":{"id":"3582617881962608","authorId":"3582617881962608","name":"Ahsiang","avatar":"https://static.tigerbbs.com/310f96e7696af85ae33ece774a483d15","vip":1,"crmLevel":11,"crmLevelSwitch":0,"authorIdStr":"3582617881962608","idStr":"3582617881962608"},"htmlText":"Oh yeah","listText":"Oh yeah","text":"Oh yeah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172028748","repostId":1105130573,"repostType":4,"repost":{"id":"1105130573","kind":"news","pubTimestamp":1626921817,"share":"https://www.laohu8.com/m/news/1105130573?lang=zh_CN&edition=full","pubTime":"2021-07-22 10:43","market":"us","language":"en","title":"Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105130573","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock","content":"(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBloomberg2021-07-22 10:43\n\n</h4>\n</header>\n<article>\n(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html\">Bloomberg</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105130573","content_text":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.\nThe move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.\nIn the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.\nModerna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.\nThe company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.\nBut the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.\nShares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.\nSkeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.\nStill, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.\nA survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.\n“In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”\nSales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":172021515,"gmtCreate":1626921905837,"gmtModify":1633769698552,"author":{"id":"3566190997597521","authorId":"3566190997597521","name":"HillaryV","avatar":"https://static.tigerbbs.com/a5e41a8432102fa946fee83eeb1384d7","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3566190997597521","idStr":"3566190997597521"},"htmlText":"Woah","listText":"Woah","text":"Woah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/172021515","repostId":1105130573,"repostType":4,"repost":{"id":"1105130573","kind":"news","pubTimestamp":1626921817,"share":"https://www.laohu8.com/m/news/1105130573?lang=zh_CN&edition=full","pubTime":"2021-07-22 10:43","market":"us","language":"en","title":"Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1105130573","media":"Bloomberg","summary":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock","content":"(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>","source":"lsy1612507957220","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Moderna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nModerna Joins Top S&P 500 Firms as Stock Value Triples<blockquote>Moderna加入标普500顶级公司行列，股价上涨两倍</blockquote>\n</h2>\n<h4 class=\"meta\">\n\nBloomberg2021-07-22 10:43\n\n</h4>\n</header>\n<article>\n(Bloomberg) -- Moderna Inc. joined the S&amp;P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.<blockquote>（彭博社）——Moderna Inc.周三加入标普500，成为该指数今年表现最好的股票——遥遥领先。</blockquote> The move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.<blockquote>此举标志着这家制药商从早期生物技术公司向向世界提供新冠疫苗的疫苗制造商的转型。2021年迄今为止，Moderna的股价涨幅略高于207%，超过了该指数现有的领先者L Brands Inc.，后者上涨了约104%。</blockquote> In the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.<blockquote>在纳入美国基准指数之前，Moderna的股价在四个交易日内上涨了30%以上，随后周二下跌了2%。其股价收高4.5%，报321.11美元，再创历史新高，市值约1290亿美元。</blockquote> Moderna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.<blockquote>Moderna的崛起很大程度上来自其在开发信使RNA疫苗方面的创新，该疫苗将人体细胞用作迷你疫苗工厂。这使得一些华尔街分析师将其看涨期权为“生物技术的特斯拉”，因为这家总部位于麻省剑桥的公司正在规划一条可能改变传染病治疗方式的路线。</blockquote> The company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.<blockquote>去年12月，该公司获得了Covid-19疫苗接种的紧急授权，仅比辉瑞公司和BioNTech SE落后一周，从而在美国生物技术公司的高端地位，仅次于艾伯维公司和安进公司。</blockquote> But the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.<blockquote>但与特斯拉的相似之处对Moderna的股票来说并不一定是好兆头。自12月特斯拉被纳入基准指数的前一天以来，该指数已下跌约6%，而该指数则上涨了近18%。该指数最近的其他成分股也表现不佳。</blockquote> Shares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.<blockquote>随着投资者调整投资组合，进入该指数的公司的股价通常会在纳入之前上涨。Moderna的股价周二已经失去动力，收盘下跌2%，至307.33美元。</blockquote> Skeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.<blockquote>对Moderna近几个月激增持怀疑态度的人指出，其管道正处于人体测试的早期阶段，而Covid-19加强注射的市场尚未完全了解。</blockquote> Still, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.<blockquote>尽管如此，最近的实验室结果显示，Moderna的疫苗会产生针对Covid-19德尔塔变异毒株的抗体。高盛分析师还预测，Moderna可能会在2023年之前向市场推出一种新的流感疫苗，最早在2024年推出流感和Covid-19疫苗的组合疫苗。该公司还在研究治疗癌症和艾滋病毒以及寨卡病毒和心脏病的新疫苗和药物。</blockquote> A survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.<blockquote>Jefferies trading desk对191家对冲基金和机构投资者的调查显示，大约73%的受访者预计Moderna股价到年底变化不大或下跌20%或更糟。投资者最关注的是delta加强剂和流感疫苗的结果，而只有13%的投资者做多Moderna。</blockquote> “In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”<blockquote>杰富瑞(Jefferies)策略师威尔·塞武什(Will Sevush)在给客户的信中写道：“最终，我们仍然不知道谁在购买这只股票，多头很少，而且相距甚远。”</blockquote> Sales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.<blockquote>据高盛称，mRNA-1273（Moderna的新冠疫苗）的销售额在2021年可能会超过华尔街预期的181亿美元。但即使是Moderna最大的爱好者、高盛分析师Salveen Richter给出的299美元的华尔街高目标价也意味着进一步撤退。</blockquote>\n<div class=\"bt-text\">\n\n\n 来源：<a href=\"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html\">Bloomberg</a>\n为提升您的阅读体验，我们对本页面进行了排版优化\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc."},"source_url":"https://finance.yahoo.com/news/moderna-joins-top-firms-p-110555617.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1105130573","content_text":"(Bloomberg) -- Moderna Inc. joined the S&P 500 on Wednesday as the index’s the best performing stock this year -- by a mile.\nThe move caps the drugmaker’s transformation from an early-stage biotech to a vaccine maker supplying Covid shots to the world. With a gain of just over 207% so far in 2021, Moderna’s share performance tops the index’s existing leader, L Brands Inc., which has risen about 104%.\nIn the runup to its inclusion in the U.S. benchmark, Moderna’s stock has made fresh highs advancing more than 30% over four sessions before a 2% dip on Tuesday. Its shares closed 4.5% higher at $321.11, another record, with a market value of about $129 billion.\nModerna’s rise has come largely from its innovations in developing messenger RNA vaccines, which use the body’s cells as mini vaccine factories. That has led some Wall Street analysts to call it the “Tesla of biotech” because the Cambridge, Massachusetts-based company is charting a course that may change the way infectious diseases are treated.\nThe company secured its place in the upper echelons of U.S. biotechs next to AbbVie Inc. and Amgen Inc. -- after receiving emergency authorization for its Covid-19 vaccination last December, just a week behind Pfizer Inc. and BioNTech SE.\nBut the parallels with Tesla don’t necessarily bode well for Moderna’s stock. Since the day before Tesla’s inclusion in the benchmark in December, it has fallen about 6% versus the index’s gain of nearly 18%. Other recent additions to the index have also underperformed.\nShares of companies entering the index typically rally ahead of the inclusion as investors adjust their portfolios. Moderna’s shares were already losing steam on Tuesday, closing 2% lower at $307.33.\nSkeptics of Moderna’s surge in recent months note that its pipeline is in the early stages of human testing while the market for Covid-19 booster shots isn’t yet fully understood.\nStill, recent lab results show Moderna’s jab produces antibodies against the Covid-19 Delta variant. Analysts at Goldman Sachs also predict Moderna could have a new flu shot on the market by 2023 and a combination of a flu and Covid-19 vaccine as soon as 2024. The company also is working on new vaccines and medicines for cancer and HIV as well as Zika and heart disease.\nA survey of 191 hedge funds and institutional investors from Jefferies trading desk indicated that roughly 73% of respondents expect Moderna shares to be little changed or to fall 20% or worse into year end. The investors were most keenly focused on a delta booster and flu shot results, while only 13% were long Moderna.\n“In the end, we still have no idea who is buying the stock,” Will Sevush, a strategist with Jefferies wrote to clients, “bulls are very few and very far between.”\nSales of mRNA-1273, as Moderna’s Covid inoculation is called, are likely to beat Wall Street consensus for $18.1 billion in 2021, according to Goldman. But even the Wall Street high price target of $299 from Moderna’s biggest enthusiast -- Goldman analyst Salveen Richter -- implies further retreat.","news_type":1,"symbols_score_info":{"MRNA":0.9}},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":99,"commentSize":15,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}